Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
10.5415/apallergy.2012.2.2.115
- Author:
Tadafumi TAMURA
1
Author Information
1. Marketing Department Sales & Marketing Division and Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Tokyo 100-8185, Japan. tadafumi.tamura@kyowa-kirin.co.jp
- Publication Type:Original Article
- Keywords:
Olopatadine hydrochloride;
Ophthalmic solution;
Substance P;
Allergic conjunctivitis;
Rat
- MeSH:
Animals;
Conjunctiva;
Conjunctival Diseases;
Conjunctivitis;
Conjunctivitis, Allergic;
Histamine;
Humans;
Injections, Intravenous;
Mast Cells;
Olopatadine Hydrochloride;
Ophthalmic Solutions;
Ovalbumin;
Rats;
Receptors, Histamine H1;
Substance P;
Tears
- From:
Asia Pacific Allergy
2012;2(2):115-121
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions. OBJECTIVE: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions. METHODS: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models. RESULTS: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva. CONCLUSION: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.
